Clinical trial
An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g
NCT00381810 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- June 22, 2006
- Completion date
- February 29, 2012
- Enrollment
- 31 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.